FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2603122015> ?p ?o ?g. }

• W2603122015 endingPage "TPS9093" @default.
• W2603122015 startingPage "TPS9093" @default.
• W2603122015 abstract "TPS9093 Background: Combined BRAF and MEK inhibition yields improved response rates and overall survival compared with BRAF inhibitor monotherapy in BRAF mutant melanoma patients(Robert et al., 2015), but the median progression-free survival is less than one year. Recent preclinical data suggest that resistant BRAF mutant melanoma cells adapt to the presence of BRAF inhibitors, but these adaptations may be disadvantageous in the absence of drug(Das Thakur et al., 2013; Moriceau et al., 2015). Further in vitro and in vivo studies suggest that intermittent dosing of BRAF inhibitors and especially BRAF + MEK inhibitor combinations may extend disease control in BRAF mutant melanoma. Based on these findings, S1320, an intergroup SWOG/ECOG randomized phase 2 clinical trial, was designed to determine whether an intermittent dosing schedule of dabrafenib and trametinib improves progression-free survival (PFS) in BRAF mutant melanoma patients treated with a standard, continuous dosing regimen. Methods: ELIGIBILITY: Patients with unresectable or metastatic BRAFV600E/K melanoma who have not been treated previously with BRAF or MEK inhibitors are eligible. Patients must have adequate end organ function and any known brain metastases must be treated prior to enrollment. DESIGN: Patients will be treated with dabrafenib at 150 mg twice daily and trametinib 2 mg twice daily during an 8 week lead in period. Patients without disease progression at the end of the lead in period will be randomized 1:1 to either continuous dosing or intermittent dosing according to a 5 weeks on, 3 weeks off schedule. Reimaging will be performed once every 8 weeks. ENDPOINTS: The primary endpoint of this study is the PFS in the continuous versus intermittent dosing arms. Secondary endpoints include the toxicity, best overall response rate, and overall survival. Early and late molecular events associated with disease progression will also be assessed using serial biopsies in a subset of patients in each arm. Support: NIH/NCI/NCTN grants CA180888, CA180819, CA180820 Clinical trial information: NCT02196181." @default.
• W2603122015 created "2017-04-07" @default.
• W2603122015 creator A5003474421 @default.
• W2603122015 creator A5007239425 @default.
• W2603122015 creator A5012911914 @default.
• W2603122015 creator A5023066362 @default.
• W2603122015 creator A5028772063 @default.
• W2603122015 creator A5053441903 @default.
• W2603122015 creator A5053602981 @default.
• W2603122015 creator A5054617686 @default.
• W2603122015 creator A5072582710 @default.
• W2603122015 creator A5073549408 @default.
• W2603122015 creator A5083745558 @default.
• W2603122015 date "2015-05-20" @default.
• W2603122015 modified "2023-10-01" @default.
• W2603122015 title "SWOG S1320: A randomized phase II trial of intermittent versus continuous dosing of dabrafenib and trametinib in BRAF^V600E/k mutant melanoma." @default.
• W2603122015 doi "https://doi.org/10.1200/jco.2015.33.15_suppl.tps9093" @default.
• W2603122015 hasPublicationYear "2015" @default.
• W2603122015 type Work @default.
• W2603122015 sameAs 2603122015 @default.
• W2603122015 citedByCount "11" @default.
• W2603122015 countsByYear W26031220152015 @default.
• W2603122015 countsByYear W26031220152017 @default.
• W2603122015 countsByYear W26031220152018 @default.
• W2603122015 countsByYear W26031220152020 @default.
• W2603122015 countsByYear W26031220152021 @default.
• W2603122015 countsByYear W26031220152022 @default.
• W2603122015 crossrefType "journal-article" @default.
• W2603122015 hasAuthorship W2603122015A5003474421 @default.
• W2603122015 hasAuthorship W2603122015A5007239425 @default.
• W2603122015 hasAuthorship W2603122015A5012911914 @default.
• W2603122015 hasAuthorship W2603122015A5023066362 @default.
• W2603122015 hasAuthorship W2603122015A5028772063 @default.
• W2603122015 hasAuthorship W2603122015A5053441903 @default.
• W2603122015 hasAuthorship W2603122015A5053602981 @default.
• W2603122015 hasAuthorship W2603122015A5054617686 @default.
• W2603122015 hasAuthorship W2603122015A5072582710 @default.
• W2603122015 hasAuthorship W2603122015A5073549408 @default.
• W2603122015 hasAuthorship W2603122015A5083745558 @default.
• W2603122015 hasConcept C126322002 @default.
• W2603122015 hasConcept C143998085 @default.
• W2603122015 hasConcept C168563851 @default.
• W2603122015 hasConcept C184235292 @default.
• W2603122015 hasConcept C2776131300 @default.
• W2603122015 hasConcept C2776694085 @default.
• W2603122015 hasConcept C2777288759 @default.
• W2603122015 hasConcept C2777658100 @default.
• W2603122015 hasConcept C2778472372 @default.
• W2603122015 hasConcept C2778830669 @default.
• W2603122015 hasConcept C2780739268 @default.
• W2603122015 hasConcept C2781249067 @default.
• W2603122015 hasConcept C2994587330 @default.
• W2603122015 hasConcept C31760486 @default.
• W2603122015 hasConcept C502942594 @default.
• W2603122015 hasConcept C535046627 @default.
• W2603122015 hasConcept C57074206 @default.
• W2603122015 hasConcept C71924100 @default.
• W2603122015 hasConcept C86803240 @default.
• W2603122015 hasConcept C95444343 @default.
• W2603122015 hasConcept C98274493 @default.
• W2603122015 hasConceptScore W2603122015C126322002 @default.
• W2603122015 hasConceptScore W2603122015C143998085 @default.
• W2603122015 hasConceptScore W2603122015C168563851 @default.
• W2603122015 hasConceptScore W2603122015C184235292 @default.
• W2603122015 hasConceptScore W2603122015C2776131300 @default.
• W2603122015 hasConceptScore W2603122015C2776694085 @default.
• W2603122015 hasConceptScore W2603122015C2777288759 @default.
• W2603122015 hasConceptScore W2603122015C2777658100 @default.
• W2603122015 hasConceptScore W2603122015C2778472372 @default.
• W2603122015 hasConceptScore W2603122015C2778830669 @default.
• W2603122015 hasConceptScore W2603122015C2780739268 @default.
• W2603122015 hasConceptScore W2603122015C2781249067 @default.
• W2603122015 hasConceptScore W2603122015C2994587330 @default.
• W2603122015 hasConceptScore W2603122015C31760486 @default.
• W2603122015 hasConceptScore W2603122015C502942594 @default.
• W2603122015 hasConceptScore W2603122015C535046627 @default.
• W2603122015 hasConceptScore W2603122015C57074206 @default.
• W2603122015 hasConceptScore W2603122015C71924100 @default.
• W2603122015 hasConceptScore W2603122015C86803240 @default.
• W2603122015 hasConceptScore W2603122015C95444343 @default.
• W2603122015 hasConceptScore W2603122015C98274493 @default.
• W2603122015 hasIssue "15_suppl" @default.
• W2603122015 hasLocation W26031220151 @default.
• W2603122015 hasOpenAccess W2603122015 @default.
• W2603122015 hasPrimaryLocation W26031220151 @default.
• W2603122015 hasRelatedWork W2109387929 @default.
• W2603122015 hasRelatedWork W2620651944 @default.
• W2603122015 hasRelatedWork W3090355867 @default.
• W2603122015 hasRelatedWork W3131642700 @default.
• W2603122015 hasRelatedWork W3194412282 @default.
• W2603122015 hasRelatedWork W4205515761 @default.
• W2603122015 hasRelatedWork W4229069946 @default.
• W2603122015 hasRelatedWork W4245662975 @default.
• W2603122015 hasRelatedWork W4366991180 @default.
• W2603122015 hasRelatedWork W4379281309 @default.
• W2603122015 hasVolume "33" @default.
• W2603122015 isParatext "false" @default.
• W2603122015 isRetracted "false" @default.

• next